Doç. Dr. Kubilay Karaboyun

Eğitim ve Uzmanlık

• 2008-2014 Cerrahpaşa Tıp Fakültesi Lisans
• 2015-2019 Kartal Dr.Lütfi Kırdar EAH, Bakırköy Dr.Sadi Konuk EAH İç Hastalıkları Uzmanlık
• 2020-2023 Tekirdağ Namık Kemal Üniversitesi Tıbbi Onkoloji Uzmanlık
• 2024 Ağrı Eğitim ve Araştırma Hastanesi Doçentlik

Deneyim

• 2014 Suluova Devlet Hastanesi Pratisyen Hekim
• 2019-2020 Akçakale Devlet Hastanesi Dahiliye Uzmanlığı
• 2024-2025 Ağrı Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanlığı
• 2025  Bağcılar Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanlığı

Kurs ve Sertifikalar

• 2023 Avrupa Medikal Onkoloji Derneği (Esmo-Board) Yeterlilik Sertifikası
• 2024 İstanbul üniversitesi Eğiticinin Eğitimi Sertifikası

• 1-     Ozkan Alan; Tugba Akın Telli; Sinem Akbas; Selver Isik; Eyyüb Çavdar; Kubilay Karaboyun; Aysegül Merc Cetinkaya; Ferhat Ekinci; Atike Pınar Erdoğan; Mahmut Büyükşimsek et al. Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations.
• 2-     E Cavdar, K Karaboyun, Y Iriagac Nanotechnology in oncology: a mini review
• 3-    O Avci, E Çavdar, Y İriağaç, K Karaboyun et al. Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration
• 4-     ES Şeber, Y İriagac, E Çavdar, K Karaboyun et al.logarithmic model for hormone receptor-positive and breast cancer patients treated with neoadjuvant chemotherapy.
• 5-     E Cavdar, K Karaboyun, Y Iriagac, OF Elcicek et al. Prognostic Value of Estrogen Receptor Co-activator AIB1 in Metastatic Breast Cancer Patients Treated with a Combination of Ribociclib and Letrozole
• 6-     K Karaboyun, E Cavdar, Y Iriagac, SY Tacar et al. Fertility Desire and Protection Practices Among Turkish Young Breast Cancer Patients Treated with Chemotherapy.
• 7-     E Cavdar, K Karaboyun, Y Iriagac, A Celikkol et al. Creatine Kinase (CK)-MB and CK-MB-to-Total-CK Ratio: A Novel Predictive Marker for Pathologic Complete Response in Breast Cancer Treated with Neoadjuvant Chemotherapy
• 8-     K Karaboyun. Evaluating inflammatory markers as predictive tools for advanced non-small cell lung cancer receiving nivolumab
• 9-     Y İriağaç, K Karaboyun, TİK ÖZÇAĞLAYAN et al. The diagnostic contribution of magnetic resonance imaging in the detection of axillary metastasis after neoadjuvant chemotherapy.
• 10- Y Iriagac, E Cavdar, K Karaboyun, SY Tacar et al. A new predictive marker for predicting response after neoadjuvant chemotherapy in hormone receptor positive/HER2-negative patients: a logarithmic model
• 11- Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci,…, S Karakaya, E Kut, F Teker, BÇ Demirel, K Karaboyunet al. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
• 12- E Cavdar, K Karaboyun, K Kara. Comprehensive analysis of the prognostic role of laboratory indices in advanced lung cancer patients
• 13- E Cavdar, Y Iriagac, K Karaboyun, O Avci. Prospective comparison of the value of CARG, G8, and VES-13 toxicity tools in predicting chemotherapy-related toxicity in older Turkish patients with cancer
• 14- O Avcı, Y İriağaç, E Çavdar, K Karaboyun. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study
• 15- Y İriağaç, E Çavdar, K Karaboyun, O Avci. The influence of visual objects and music on anxiety levels of breast cancer patients scheduled to experience chemotherapy for the first time: a prospective randomized clinical study
• 16- K Karaboyun, Y İriağaç, E Çavdar et al. Comparison of three equations for estimating glomerular filtration rate as predictors of cisplatin-related acute kidney injury in lung cancer patients with normal renal function
• 17- E Cavdar, Y Iriagac, K Karaboyun et al. Prognostic Role of Lymphovascular Invasion and Perineural Invasion in Breast Cancer Treated with Neoadjuvant Chemotherapy.
• 18- K Karaboyun, E Cavdar, Y Irıagac, A Celebı et al. Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
• 19- I Yakup, C Eyyup, K Kubilay, A Okan et al. Immunogenicity and safety of the CoronaVac vaccine in patients undergoing treatment for breast and lung cancer.
• 20- Seber E. S., Iriagac Y., Cavdar E., Karaboyun K., Avci O., Yolcu A et al. Efficacy of neoadjuvant chemotherapy in lobular and rare subtypes of breast cancer
• 21- E Cavdar, K Karaboyun, Y Iriagac et al. Use of Complementary Therapy in Lung Cancer Patients Treated with Chemotherapy and its Effect on Survival: A Cross-sectional Study
• 22- K Karaboyun, S Girgin, M Yılmaz et al. Mortalidad a los 90 días y al año y resultados renales de pacientes que iniciaron tratamiento con hemodiálisis por primera vez
• 23- K Karaboyun, ES Şeber. The prognostic role of neutrophil/lymphocyte ratio and monocyte/lymphocyte ratio in advanced stage gastric cancer patients receiving chemotherapy: a single center experience
• 24- E Cavdar, Y Iriagac, K Karaboyun, O Avci, ES Seber. Understanding breast cancer from the patients' perspective
• 25- Y Iriagac, E Cavdar, K Karaboyun et al. Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib
• 26- E ÇAVDAR, K KARABOYUN et al. Survival Impact of Adjuvant Chemoradiotherapy in Resected Pancreatic Cancer
• 27- K Karaboyun, E Çavdar, Y İriağaç et al. The Role of Interleukin-20 in Paclitaxel-Associated Peripheral Neuropathy in Non-Metastatic Breast Cancer Patients Receiving Chemotherapy
• 28- K Karaboyun, Y Iriagac, E Cavdar, O Avci, ES Seber. A New Mortality Prediction Model in Advanced Stage Cancer Patients Requiring Hospitalisation while Receiving Active Systemic Therapy
• 29- E Cavdar, K Karaboyun, Y Iriagac, O Avciet al. Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study
• 30- K Karaboyun, M Öznur, A Yolcu, Y İriağaç et al. Investigation of the Effect of Low-positive HER-2 on Neoadjuvant Chemotherapy Response in Hormone-positive Breast Cancer Patients
• 31- Halil İbrahim Ellez ,…, Ertuğrul Bayram, Kubilay Karaboyun et al. Denosumab administration in breast, prostate and lung cancer with chronic kidney disease–a retrospective multicenter Turkish Oncology Group (TOG) study
• 32- K Karaboyun, A Yolcu. Prognostic factors influencing regorafenib treatment outcomes in metastatic colorectal cancer
• 33- Y İRİAĞAÇ, K KARABOYUN et al. Effects of COVID-19 Pandemic on Diagnosis-treatment Process in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
• 34- T YETİŞYİĞİT, K KARABOYUN. Lenfomagenez. Turkiye Klinikleri Medical Oncology
• 35- K KARABOYUN, NS DEMİRCİ - Baş-Boyun Kanserlerinde İmmünoterapi.2022 - turkiyeklinikleri.com
• Kkaraboyun, Asakin. Geleneksel Çin Tıbbı. KANSER HASTALARININ BAŞVURDUĞU GELENEKSEL VE TAMAMLAYICI TEDAVILER.